Subcutaneous epcoritamab with rituximab plus lenalidomide (R-2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial
Falchi, L. Leppa, S. Wahlin, B. E. Nijland, M. Christensen, J. H. De Vos, S. Holte, H. Linton, Kim M Abbas, A. Wang, L. W.
Falchi, L.
Leppa, S.
Wahlin, B. E.
Nijland, M.
Christensen, J. H.
De Vos, S.
Holte, H.
Linton, Kim M
Abbas, A.
Wang, L. W.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Falchi L, Leppa S, Wahlin BE, Nijland M, Christensen JH, De Vos S, et al. Subcutaneous epcoritamab with rituximab plus lenalidomide (R-2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301985.